In DepthInfectious Disease

As Ebola epidemic draws to a close, a thin scientific harvest

Science  01 Jan 2016:
Vol. 351, Issue 6268, pp. 12-13
DOI: 10.1126/science.351.6268.12

You are currently viewing the summary.

View Full Text

Summary

As the Ebola epidemic exploded in the summer of 2014, a frenzied effort began to test vaccines and drugs in Liberia, Sierra Leone, and Guinea. But so far, results from just one clinical trial have appeared in a peer-reviewed journal; it showed Merck's Ebola to be remarkably successful. A dozen other trials have yet to be published. Many didn't deliver a clear answer because they failed to enroll the planned number of participants. Others did recruit enough patients but didn't use a randomized controlled trial design, which weakened results. Still others were halted early. One last hope for an uplifting result remains: an ongoing study of ZMapp, a promising antibody cocktail.